SMALLCAP - FUNDAMENTAL & TECHNICAL - ATOS Long to 15
Price Action:
- Contrarian investing and whale hunting lead me to this stock... when I see high effort to short, I see opportunity. Usually when institutions find a stock they want, they will attack with naked shorting and FUD to drive the price down and shake out retail.
- 4% inst. owned, +330% inst. transactions, confirming my suspicions.
- 70M Float, this one will be hard to keep down.
- Take a look at the huge accumulating since March. Somebody knows something is up.
Fundamentals:
"The AT-301 formulation was designed to work like a mucosal vaccine, blocking entry of the virus into the cells to begin with and thus, hopefully, preventing a COVID-19 infection"
"AT-301 is being developed with a nasal spray delivery mechanism because many COVID-19 patients are infected via the nasal passage. Collectively, the components of AT-301 are believed to help maintain a protective mucosal like layer within the nasal cavity with both anti-viral properties and protective mucosal like barrier that may lead to lower infectivity and reduced symptoms in COVID-19 patients due to their interference with the spike protein of the virus in the nasal cavity and upper respiratory tract. Atossa’s nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains (RBD) via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier."
"The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days."
- Potential breakthroughs in cancer and COVID research... Pharma is taking off, this company WILL be pumped
Could be the next big one.. I won't be sleeping on this opportunity.
- Contrarian investing and whale hunting lead me to this stock... when I see high effort to short, I see opportunity. Usually when institutions find a stock they want, they will attack with naked shorting and FUD to drive the price down and shake out retail.
- 4% inst. owned, +330% inst. transactions, confirming my suspicions.
- 70M Float, this one will be hard to keep down.
- Take a look at the huge accumulating since March. Somebody knows something is up.
Fundamentals:
"The AT-301 formulation was designed to work like a mucosal vaccine, blocking entry of the virus into the cells to begin with and thus, hopefully, preventing a COVID-19 infection"
"AT-301 is being developed with a nasal spray delivery mechanism because many COVID-19 patients are infected via the nasal passage. Collectively, the components of AT-301 are believed to help maintain a protective mucosal like layer within the nasal cavity with both anti-viral properties and protective mucosal like barrier that may lead to lower infectivity and reduced symptoms in COVID-19 patients due to their interference with the spike protein of the virus in the nasal cavity and upper respiratory tract. Atossa’s nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains (RBD) via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier."
"The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days."
- Potential breakthroughs in cancer and COVID research... Pharma is taking off, this company WILL be pumped
Could be the next big one.. I won't be sleeping on this opportunity.
Comment:
I am thinking we see 5.5 at the minimum this wave:
